Hereditary photodermatosis
MONDO:0015951Hereditary photodermatoses are a spectrum of rare photosensitive disorders that are often caused by genetic deficiency or malfunction of various components of the DNA repair pathway. This results clinically in extreme photosensitivity, with many syndromes exhibiting an increased risk of cutaneous malignancies.
Also known as: photogenodermatosis, photogénodermatose, genetic photosensitivity, genetic skin photosensitivity
33 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Heartburn drug could ease painful sun sensitivity
Disease control CompletedThis Phase 2 trial tested whether oral cimetidine (Tagamet), a common heartburn drug, can reduce light sensitivity in people with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). These genetic conditions cause severe pain from sunlight exposure. The study en…
Phase: PHASE2 • Sponsor: Amy K. Dickey, M.D. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
EPP drug levels under the microscope: afamelanotide study completed
Disease control CompletedThis study looked at how the drug afamelanotide (Scenesse) behaves in the bodies of 28 people with erythropoietic protoporphyria (EPP), a rare condition that causes severe pain on sun exposure. Researchers measured the drug's concentration in the blood after a single implant. The…
Phase: PHASE1, PHASE2 • Sponsor: Clinuvel Europe Limited • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug offers hope for patients who Can't tolerate sunlight
Disease control CompletedThis study tested a drug called bitopertin in 75 adults with erythropoietic protoporphyria (EPP), a rare condition that causes severe pain from sunlight exposure. The goal was to see if the drug is safe and can lower levels of a harmful substance in the blood. Participants receiv…
Phase: PHASE2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug aims to let sunlight-sensitive patients enjoy the sun longer
Symptom relief CompletedThis study tested a drug called MT-7117 in 165 adults and adolescents (ages 12-75) with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), conditions that cause severe pain from sunlight exposure. The goal was to see if the drug could delay the first symptoms o…
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New drug may let people with rare sun allergy enjoy the outdoors longer
Symptom relief CompletedThis study tested a drug called MT-7117 in 184 people aged 12 to 75 with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain from sunlight. The goal was to see if the drug could delay the first signs of sun sensitivity (bur…
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
New pill could let EPP patients enjoy the sun without pain
Symptom relief CompletedThis phase 2 trial tested a drug called MT-7117 in 102 adults with erythropoietic protoporphyria (EPP), a rare condition that causes severe pain from sunlight. Participants took either a low dose, high dose, or placebo daily for 16 weeks. The goal was to see if the drug could inc…
Phase: PHASE2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Scientists study rare DNA repair diseases to unlock cancer prevention secrets
Knowledge-focused CompletedThis study looked at people with three rare genetic conditions—xeroderma pigmentosum (XP), Cockayne syndrome (CS), and trichothiodystrophy (TTD)—that affect the body's ability to repair DNA. Researchers examined 709 participants to understand how these defects relate to cancer ri…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Rare disease detection: new study measures porphyria prevalence in symptomatic patients
Knowledge-focused CompletedThis completed study aimed to find out how many patients with a certain set of symptoms actually have acute hepatic porphyria (AHP), a rare metabolic disorder. Researchers enrolled 150 adults aged 18 to 60 who had severe abdominal pain along with neurological symptoms like limb w…
Sponsor: Association pour la Recherche en Medecine Interne • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
AI could cut skin specialist wait times, study hints
Knowledge-focused CompletedThis study tested an artificial intelligence algorithm designed to help primary care doctors decide whether a patient with a skin condition really needs to see a dermatologist. Researchers enrolled 200 adults with skin problems and had their doctors take photos of the affected ar…
Sponsor: AI Labs Group S.L • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC